CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 15 enrolled
Drug / intervention
brachytherapy +1 moreradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01045187
NCT01045187N/ACompleted
CompareCT.gov

Feasibility Study Using the Xoft Axxent Electronic Brachytherapy System for the Treatment of Endometrial Cancer

Xoft, Inc.·interventional·Posted Jan 8, 2010·Updated Aug 1, 2012

In Brief

A clinical study evaluating brachytherapy and Xoft Axxent Electronic Brachytherapy System for Endometrial Cancer. Completed, enrolled 15 participants across 6 sites.

Detailed Summary

Multicenter, non-randomized, feasibility study to evaluate the treatment and assess acute safety of the FDA Cleared Axxent Electronic Brachytherapy System and vaginal applicator for intracavitary vaginal cuff treatment according to the physician's current standard of care.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometrial Cancer
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 8, 2010
Enrollment StartOct 1, 2008
Primary CompletionJan 1, 2010
Study CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.5 years ago

Interventions

brachytherapyradiation

Electronic brachytherapy dose 21 Gy or 22 Gy in 3-4 fractions prescribed to 5mm depth, or electronic brachytherapy 16-18 Gy if EBRT is administered.

Xoft Axxent Electronic Brachytherapy Systemradiation

21-22 Gy in 3-4 fractions to 5mm or 16-18 Gy in 3 fractions prescribed to the surface.